Literature DB >> 21646855

Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer.

A Polachek1, D Hirsch, G Tzvetov, S Grozinsky-Glasberg, I Slutski, J Singer, R Weinstein, I Shimon, C A Benbassat.   

Abstract

BACKGROUND: Thyroglobulin is an excellent biological marker of persistent or recurrent thyroid cancer during long-term follow-up. Most studies investigated its diagnostic value but not its prognostic value over time. We aim to study the prognostic value of thyroglobulin levels early after total thyroidectomy, before iodine ablation.
METHODS: The study was based on the Rabin Medical Center registry of patients with non-medullary thyroid carcinoma. Data were collected on the clinical, laboratory, and outcome characteristics of 420 consecutive patients followed at our institution for whom early post-operative pre-ablation thyroglobulin values (baseline thyroglobulin) were available.
RESULTS: Patients were classified into 4 groups by baseline thyroglobulin level: 0-2, 2-10, 10-100, and >100 ng/ml. Higher levels were associated with a shift toward male gender (p=0.01), larger tumor size (p=0.02), and a more extensive disease (p<0.0001). They were also related to disease persistence and evidence of disease at last follow-up (p<0.0001). The 10 ng/ml cut-off level identified patients with persistent disease with a sensitivity and specificity of 73%, positive predictive value of 43%, and negative predictive value of 89%. On multivariate analysis, the following variables were predictive of persistent disease: baseline thyroglobulin level, male gender, lymph-node involvement, distant metastases, higher tumor invasiveness, and larger tumor size. However, the predictive power of baseline thyroglobulin level was relatively weak (odds ratio 1.002, 95% confidence interval 1.00-1.04).
CONCLUSIONS: In patients with well-differentiated thyroid cancer, a post-thyroidectomy thyroglobulin level <10 ng/ml is associated with a low probability of having persistent disease and can be used combined with other disease characteristics for decisions regarding treatment and follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646855     DOI: 10.3275/7768

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.

Authors:  Karen A Heemstra; Ying Y Liu; Marcel Stokkel; Job Kievit; Eleonora Corssmit; Alberto M Pereira; Johannes A Romijn; Johannes W A Smit
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up.

Authors:  Robbert B T Verkooijen; Daphne Rietbergen; Jan W Smit; Johannes A Romijn; Marcel P M Stokkel
Journal:  Eur J Endocrinol       Date:  2007-01       Impact factor: 6.664

4.  Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis.

Authors:  Shu-Hua Huang; Pei-Wen Wang; Yu-Erh Huang; Fong-Fu Chou; Rue-Tsuan Liu; Shih-Chen Tung; Jung-Fu Chen; Ming-Chun Kuo; Jing-Rong Hsieh; Hsin-Hung Hsieh
Journal:  Thyroid       Date:  2006-12       Impact factor: 6.568

5.  Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.

Authors:  F Grünwald; C Menzel; R Fimmers; P O Zamora; H J Biersack
Journal:  J Nucl Med       Date:  1996-12       Impact factor: 10.057

Review 6.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

7.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

8.  Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.

Authors:  A Iervasi; G Iervasi; M Ferdeghini; C Solimeo; A Bottoni; L Rossi; C Colato; G C Zucchelli
Journal:  Clin Endocrinol (Oxf)       Date:  2007-06-06       Impact factor: 3.478

9.  Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.

Authors:  M Schlumberger; A Hitzel; M E Toubert; C Corone; F Troalen; M H Schlageter; F Claustrat; S Koscielny; D Taieb; M Toubeau; F Bonichon; F Borson-Chazot; L Leenhardt; C Schvartz; C Dejax; I Brenot-Rossi; M Torlontano; F Tenenbaum; S Bardet; F Bussière; J J Girard; O Morel; O Schneegans; J L Schlienger; A Prost; D So; F Archambeaud; M Ricard; E Benhamou
Journal:  J Clin Endocrinol Metab       Date:  2007-04-10       Impact factor: 5.958

10.  Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.

Authors:  C F A Eustatia-Rutten; J W A Smit; J A Romijn; E P M van der Kleij-Corssmit; A M Pereira; M P Stokkel; J Kievit
Journal:  Clin Endocrinol (Oxf)       Date:  2004-07       Impact factor: 3.478

View more
  12 in total

Review 1.  Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Authors:  M G Castagna; S Cantara; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-06-27       Impact factor: 4.256

2.  Indications for the gasless transaxillary robotic approach to thyroid surgery: experience of forty-seven procedures at the american hospital of paris.

Authors:  Patrick Aidan; Helen Pickburn; Hervé Monpeyssen; Gilles Boccara
Journal:  Eur Thyroid J       Date:  2013-06-14

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.

Authors:  Mehmet Hakan Korkmaz; Bülent Öcal; Güleser Saylam; Erman Çakal; Ömer Bayır; Esra Tutal; Emel Çadallı Tatar
Journal:  Langenbecks Arch Surg       Date:  2017-02-21       Impact factor: 3.445

5.  Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.

Authors:  Arnoldo Piccardo; Matteo Puntoni; Gianluca Bottoni; Giorgio Treglia; Luca Foppiani; Mattia Bertoli; Ugo Catrambone; Anselmo Arlandini; Bassam Dib; Vania Altrinetti; Michela Massollo; Irene Bossert; Manlio Cabria; Francesco Bertagna; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-14       Impact factor: 9.236

6.  Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.

Authors:  Seunggyun Ha; So Won Oh; Yu Kyeong Kim; Do Hoon Koo; Young Ho Jung; Ka Hee Yi; June-Key Chung
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

7.  Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response.

Authors:  Lihua Wang; Canhua Yun; Fengyan Huang; Juan Xiao; Yanli Ju; Fang Cheng; Wei Zhang; Hongying Jia
Journal:  Cancer Manag Res       Date:  2021-07-05       Impact factor: 3.989

Review 8.  Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process.

Authors:  Gal Omry-Orbach
Journal:  Rambam Maimonides Med J       Date:  2016-01-28

9.  Role of Preablative Stimulated Thyroglobulin in Prediction of Nodal and Distant Metastasis on Iodine Whole-Body Scan.

Authors:  Meghana Prabhu; Sanju Samson; Avinash Reddy; Sunil Hejaji Venkataramanarao; Naveen Hedne Chandrasekhar; Vijay Pillai; Vivek Shetty; Moni Abraham Koriokose; Bushan Vaidhya; Subramanian Kannan
Journal:  Indian J Nucl Med       Date:  2018 Apr-Jun

10.  Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer.

Authors:  Germán A Jimenez Londoño; Ana Maria Garcia Vicente; Julia Sastre Marcos; Francisco Jose Pena Pardo; Mariano Amo-Salas; Manuel Moreno Caballero; Maria Prado Talavera Rubio; Beatriz Gonzalez Garcia; Niletys Dafne Disotuar Ruiz; Angel Maria Soriano Castrejón
Journal:  Eur Thyroid J       Date:  2018-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.